Investor Presentaiton
Investor presentation
First three months of 2017
Slide 82
Liver-preferential meal time insulin analogue has potential
to reduce hypoglycaemia and weight gain
Liver:
The liver is important for insulin action
sc insulin sc liver-preferential prandial insulin
Glucose production
Muscle:
Glucose uptake
Endogenous insulin
Fat:
Glucose uptake
•
•
•
Rationale and expected benefits of
physiologically distributed insulin
Rationale
Elevated hepatic glucose release drives overall higher PPG in
people with type 2 diabetes compared to healthy individuals¹
>50% of endogenous insulin secretion is cleared by the liver
Insulinisation of peripheral tissues with current insulin
analogues is higher than for endogenous insulin
Potential benefits
Mimics physiology of insulin distribution secreted from
pancreas
Less hypoglycaemia
Less weight gain
Next steps
Phase 1 trial with liver-preferential mealtime insulin
(NN1406) initiated
PPG: post prandial glucose
1 Woerle HJ et al. Am J Physiol Endocrinol Metab 2006;290:E67-E77
Note: Mode of action for fast-acting insulin aspart
sc: subcutaneous
changing
diabetes®
novo nordiskView entire presentation